Figure 3.

Change from baseline in (A) trough FEV₁ and (B) peak FEV₁ at Week 24 in ATTAIN study.

Notes: Data reported as least squares mean (standard error). *P<0.0001 for both treatments vs placebo. There were no statistically significant differences between the two aclidinium arms. Reproduced with permission of the European Respiratory Society: Eur Respir J, October 2012 40:830–836; published ahead of print March 22, 2012, doi:10.1183/09031936.00225511.³²

Abbreviations: ATTAIN, Aclidinium To Treat Airway obstruction In COPD patieNts; BID, twice daily; FEV₁, forced expiratory volume in 1 second.